NewLimit
Last verified 2026-06-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $347.0Mattributed |
|---|---|
| Latest round | series-b, $130.0M, 2025-05-01attributed |
| Founded | 2022 |
| Headquarters | South San Francisco, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | newlimit.com |
NewLimit is a biotechnology company developing medicines that restore youthful function to old cells by reprogramming the epigenome. It targets patients with age-related diseases of the liver, immune, and vascular systems. Rather than altering DNA, it reverses cellular aging through epigenetic reprogramming guided by single-cell genomics.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-05-01 | series-b | $130.0M | undisclosed |
Detected tech stack
cloudflare, doubleclick floodlight, google font api, google hosted libraries, hsts, http/3, jquery 3.5.1, mysql, php, vercel speed insights, wordpress
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $130.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $347.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | newlimit.com, read 2026-06-07 |
| Description | self-reported | newlimit.com, read 2026-06-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.